EGFR and non-small cell lung carcinoma: Serizawa et al. reported that efatutazone inhibited cell motility by antagonizing the TGF-β/Smad2 pathway and effectively prevented metastasis in NSCLC patients with acquired resistance to EGFR-TKI [107].